



CUMULATIVE 12 MONTH ROLLING ANTIBIOGRAM (NON-URINES) / JUN 2021
46867240 KINDRED HOSPITAL SEATTLE-FIRST

# ISOLATES	ANTIMICROBIAL SUSCEPTIBILITIES - PERCENT SUSCEPTIBLE										
	EC	ENTBSP	ENTS	ENTS ENTFA	KLEBSP	PROTSP	PSEUAE	SERRSP	STAPA	STAPA MRSA	STAPA MSSA
	29*	26*	27*	24*	59	23*	88	21*	68	21*	47
AMIKACIN							98				
AMOXICILLIN/CA	62	0			53	100		5			
AMPICILLIN	45				0	83					
CEFAZOLIN		0			0			0			
CEFEPIME	75	62			66	91	64	95			
CEFTAZIDIME							68				
CEFTRIAZONE	59				39	91		75			
CEFURXIME	55	0			41	91		0			
CIPROFLOXACIN	79	96			71	87	83	100	66	10	91
CLINDAMYCIN									72	48	83
ERTAPENEM	93				97	100					
ERYTHROMYCIN									47	10	64
GENTAMICIN	86	96			95	100	84	95	97	95	98
IMIPENEM	90	85			76		74				
LEVOFLOXACIN	79	100			75	87	65	100	66	10	91
LINEZOLID									100	100	100
MEROPENEM	93	81			81	100	81	95			
MOXIFLOXACIN									91		91
NITROFURANTOIN					26						
OXACILLIN									69	0	100
PENICILLIN			93	100					0	0	0
PIPERACILLIN							75				
PIPERACILLIN/TAZOBACTAM	86				69	100					
QUINUPRISTIN/DALFOPRISTIN									100		100

ORGANISM ACRONYM KEY

EC	Escherichia coli	PSEUAE	Pseudomonas aeruginosa
ENTBSP	Enterobacter species	SERRSP	Serratia species
ENTS	Enterococcus species	STAPA	Staphylococcus aureus
ENTS ENTFA	Enterococcus faecalis	STAPA MRSA	Staphylococcus aureus /MRSA
KLEBSP	Klebsiella species	STAPA MSSA	Staphylococcus aureus /MSSA
PROTSP	Proteus species		

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUMULATIVE 12-MONTH ROLLING ANTI BIOGRAM (URINES) / JUN 2021
46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL SUSCEPTIBILITIES - PERCENT SUSCEPTIBLE									
	EC	ENTS	KLEBSP	PROTSP	PSEUAE					
# ISOLATES	37	24*	33	21*	41					
AMIKACIN					100					
AMOXICILLIN/CA	62		82							
AMPICILLIN	32		0	67						
CEFEPIME	81		84	95	73					
CEFTAZIDIME					73					
CEFTRIAZONE	73			95						
CEFUROXIME	51		64	76						
CIPROFLOXACIN	76	63	82	81	83					
ERTAPENEM	100		100	100						
GENTAMICIN	84		97	100	98					
IMIPENEM	100		100		73					
LEVDFLOXACIN	76	63	94	81	78					
MEROPENEM	100		100	100	78					
NITROFURANTOIN	97	79	30	5						
PENICILLIN		71								
PIPERACILLIN					85					
PIPERACILLIN/TAZOBACTAM	92		96	95						
TETRACYCLINE	76	25	61	10						
TICARCILLIN					70					
TOBRAMYCIN	81		85	95	100					
TRIMETH-SULFA	73		73	81						
VANCOMYCIN		79								

ORGANISM ACRONYM KEY

EC Escherichia coli
 ENTS Enterococcus species
 KLEBSP Klebsiella species
 PROTSP Proteus species
 PSEUAE Pseudomonas aeruginosa

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021
46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL SUSCEPTIBILITIES - PERCENT SUSCEPTIBLE										
	ACIS	ALCX	BURKSP	CHRBSP	CITRSP	DIPTHE	EC	EGGELE	ENTBSP	ENTS	ENTS ENTFA
# ISOLATES	9*	4*	6*	1*	11*	1*	59	1*	32	49	40
AMOXICILLIN/CA							64		0		
AMPICILLIN							41				
CEFAZOLIN							4		0		
CEFEPIME							79		59		
CEFTRIAZONE							68				
CEFUROXIME							58		0		
CIPROFLDAXIN							80		97	63	
ERTAPENEM							96				
GENTAMICIN							86		97		
IMIPENEM							95		84		
LEVOFLOXACIN							80		100	63	
MEROPENEM							97		81		
NITROFURANTOIN							94		50	79	
PENICILLIN										82	98
PIPERACILLIN/TAZOBACTAM							88				
TETRACYCLINE							80		72	25	
TOBRAMYCIN							86		97		
TRIMETH-SULFA							78		81		
VANCOMYCIN										90	100

ORGANISM ACRONYM KEY

ACIS	Acinetobacter species	EC	Escherichia coli
ALCX	Achromobacter species	EGGELE	Eggerthella lenta
BURKSP	Burkholderia species	ENTBSP	Enterobacter species
CHRBSP	Chryseobacterium gleum	ENTS	Enterococcus species
CITRSP	Citrobacter species	ENTS ENTFA	Enterococcus faecalis
DIPTHE	Diphtheroids		

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021
46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL SUSCEPTIBILITIES - PERCENT SUSCEPTIBLE										
	ENTS ENTFM	KLEBSP	MORM	PROTSP	PROVSP	PSEUAE	PSEUSP	RAOUOR	SERRSP	STAPA	STAPA MRSA
# ISOLATES	4+	79	7+	34	3+	107	4+	1+	22+	68	21+
AMIKACIN						98					
AMOXICILLIN/CA		65		100					5		
AMPICILLIN		0		74							
CEFAZOLIN		0							0		
CEFEPIME		72		94		66			95		
CEFTAZIDIME						70					
CEFTRIAZONE		46		94					76		
CEFUROXIME		51		82					0		
CIPROFLOXACIN		76		82		83			100	66	10
CLINDAMYCIN										72	48
ERTAPENEM		98		100							
ERYTHROMYCIN										47	10
GENTAMICIN		96		100		87			95	97	95
IMIPENEM		82				77					
LEVOFLOXACIN		79		82		68			100	66	10
LINEZOLID										100	100
MEROPENEM		86		100		82			95		
MOXIFLOXACIN										91	
NITROFURANTOIN		29		3							
OXACILLIN										69	0
PENICILLIN										0	0
PIPERACILLIN						78					
PIPERACILLIN/TAZOBACTAM		80		97							
QUINUPRISTIN/DALFOPRISTIN										100	

ORGANISM ACRONYM KEY

ENTS ENTFM	Enterococcus faecium	PSEUSP	Pseudomonas sp.(non-aeruginosa)
KLEBSP	Klebsiella species	RAOUOR	Raoultella ornithinolytica
MORM	Morganella morganii	SERRSP	Serratia species
PROTSP	Proteus species	STAPA	Staphylococcus aureus
PROVSP	Providencia species	STAPA MRSA	Staphylococcus aureus /MRSA
PSEUAE	Pseudomonas aeruginosa		

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.

CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021
46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL SUSCEPTIBILITIES - PERCENT SUSCEPTIBLE									
	STAPA MSSA	STAPCN	STEM	STREPN	STRESP					
# ISOLATES	47	16*	27*	1*	2*					
CEFTAZIDIME			37							
CHLORAMPHENICOL			56							
CIPROFLOXACIN	91									
CLINDAMYCIN	83									
ERYTHROMYCIN	64									
GENTAMICIN	98									
LEVOFLOXACIN	91		89							
LINEZOLID	100									
MOXIFLOXACIN	91									
OXACILLIN	100									
PENICILLIN	0									
QUINUPRISTIN/DALFOPRISTIN	100									
RIFAMPIN	100									
TETRACYCLINE	98									
TRIMETH-SULFA	100		93							
VANCOMYCIN	100									

ORGANISM ACRONYM KEY

STAPA MSSA Staphylococcus aureus /MSSA
 STAPCN Staphylococcus, coagulase neg
 STEM Stenotrophomonas maltophilia
 STREPN Streptococcus pneumoniae
 STRESP Streptococcus viridans

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).